5 Biotechs Releasing Highly Anticipated Data at ASCO
May 19, 2017
By Mark Terry, BioSpace.com Breaking News Staff
The upcoming American Society of Clinical Oncology (ASCO), being held in Chicago from June 2 through 6, is a top showcase for biopharma companies to release data from ongoing clinical trials. For investors, abstracts were just released, and stocks are already moving in anticipation. Here’s a look at five biotech companies in the cancer market and their upcoming releases.
Bluebird bio (BLUE), based in Cambridge, Mass., will present interim data from its Phase I trial of bb2121, its anti-BCMA CAR-T cell therapy in relapsed/refractory multiple myeloma. The abstract (#3010) is titled, “First-in-Human Multicenter Study of bb2121 anti-BCMA CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma: Updated Results.”
Bluebird bio stock is currently trading for $88.45.
Headquartered in Cambridge, Mass., Epizyme (EPZM) will present a poster titled “Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with INI1 negative epithelioid sarcoma (NCT02601950).” This is an update of the trial, which also follows a positive meeting with the U.S. Food and Drug Administration (FDA) to discuss its registration strategy for tazemetostat, which received accelerated approval based on the Phase II trial. It expects to submit a New Drug Application (NDA) in 2018.
Epizyme stock is currently trading for $17.10.
Based in Seattle, Juno Therapeutics (JUNO) will present clinical updates in partnership with its collaborators on JCAR017 and JCAR014. New data from the Phase I trial of JCAR017 in adult patients with relapsed or refractory aggressive non-Hodgkin’s Lymphoma (NHL) will be presented. And updated safety data from the ongoing Phase I trial of JCAR014 in adults with relapsed or refractory acute lymphocytic leukemia (ALL), NHL or chronic lymphocytic leukemia (CLL) will be presented. In addition, the JCAR014 presentation will touch on data regarding biomarkers for early identification of cytokine release syndrome (CRS) and neurotoxicity (NT).
Juno Therapeutics stock is currently trading for $25.
Headquartered in Santa Monica, Calif, Kite Pharma (KITE) will present six posters and/or presentations about its axicabtagene ciloleucel (KTE-C19). The poster presentation is titled, “Clinical and biologic covariates of outcomes in ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C29) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).
Kite Pharma stock is currently trading at $72.49.
Based in Utrecht, the Netherlands, Merus BV (MRUS) will present the results of its first-in-human Phase I/II trial of MCLA-128 in solid tumors, as well as final Phase I data in HER2-positive metastatic breast cancer (MBC) from the Phase II part of the trial. MCLA-127 is designed to block HER3/heregulin-dependent tumor growth and survival in addition to enhancing immune-mediated cytotoxicity in tumors.
“These clinical results demonstrate that single agent MCLA-128 is active and well tolerated in heavily pretreated metastatic breast cancer patients,” Joseph Tabernero, head of Medical Oncology and the Institute of Oncology at Vall d’Hebron University Hospital, in a statement. “This positions MCLA-128 as a promising agent for further development as combination therapy in the treatment paradigm of metastatic breast cancer. I look forward to seeing how these results translate in the planned Phase II combination studies.”
Merus stock is currently trading for $19.61.